Biomedical company Exalenz Bioscience Ltd.'s (TASE:EXEN) share price was up sharply in trading today, after the company announced that it had contracted an exclusive agreement for the supply of its flagship product to LabCorp.
Exalenz Bioscience develops and markets a medical device for testing breathing in order to diagnose and manage diseases in the digestive tract and the liver. The company sells its BreathID devices together with disposable kits needed for the tests. Exalenz Bioscience is currently active in 400 medical centers in the US in diagnosing the presence of H. pylori bacteria using its breathing test.
